Loading...
•
Nov 30, 2024
Walgreens Q1 2025 Earnings Report
Walgreens reported Q1 2025 results, showing sales increase but a loss per share, with adjusted EPS impacted by lower U.S. retail sales and prior year gains, offset by cost savings and U.S. Healthcare growth; maintained full year adjusted EPS guidance.
Key Takeaways
Walgreens Boots Alliance reported a 7.5% increase in sales to $39.5 billion for the first quarter of fiscal year 2025. However, the company experienced a loss per share of $0.31, although adjusted EPS was $0.51. The company is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.
First quarter sales increased 7.5% year-over-year to $39.5 billion.
Loss per share was $0.31, including costs related to the Footprint Optimization Program.
Adjusted EPS was $0.51, driven by lower U.S. retail sales and prior year sale-leaseback gains, partly offset by cost savings and growth in U.S. Healthcare.
Fiscal 2025 adjusted EPS guidance maintained at $1.40 to $1.80.
Revenue by Segment
Forward Guidance
Walgreens is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.
Positive Outlook
- Growth in U.S. Healthcare
- Growth in International
- Disciplined execution against 2025 priorities
- Optimizing footprint
- Controlling operating costs
Challenges Ahead
- Decline in U.S. Retail Pharmacy
- Higher adjusted effective tax rate
- Lower contributions from sale-leaseback
- Lower Cencora earnings
- Turnaround will take time
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...